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Abstract
Background Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metas-
tasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer 
(nmCRPC). In this population, polypharmacy for age-related comorbidities is common and may increase drug–drug interaction 
(DDI) risks. Preclinical/phase I study data suggest darolutamide has a low DDI potential—other than breast cancer resistance 
protein/organic anion transporter protein substrates (e.g., statins), no clinically relevant effect on comedications is expected.
Objective Our objective was to evaluate the effect of commonly administered drugs on the pharmacokinetics of darolutamide 
and the effect of comedications potentially affected by darolutamide on safety in patients with nmCRPC.
Patients and Methods Comorbidities and comedication use in the 1509 ARAMIS participants treated with darolutamide 
600 mg twice daily or placebo were assessed. A population pharmacokinetic analysis evaluated whether comedications 
affected the pharmacokinetics of darolutamide in a subset of 388 patients. A subgroup analysis of adverse events (AEs) in 
statin users versus nonusers was conducted.
Results Most participants (median age 74 years) had at least one comorbidity (98.4% in both arms) and used at least one come-
dication (98.7% with darolutamide vs. 98.0% with placebo); these were similar across study arms. Despite frequent use of come-
dications with DDI potential, no significant effects on darolutamide pharmacokinetics were identified. Comedications included 
lipid-modifying agents (34.5%), β-blockers (29.7%), antithrombotics (42.8%), and systemic antibiotics (26.9%). AE incidence 
was similar across study arms in statin users and nonusers. Study limitations include the small sample size for sub-analyses.
Conclusions These analyses suggest the pharmacokinetic profile of darolutamide is not affected by a number of commonly 
administered drugs in patients with nmCRPC. Although pharmacokinetic data have indicated that darolutamide has the 
potential to interact with rosuvastatin, used to assess DDI in these studies, this finding did not seem to translate into increased 
AEs due to statin use in the ARAMIS trial.
Clinicaltrials.gov identifier: NCT02200614.
Plain Language Summary
Background Darolutamide is a medicine used to treat men with prostate cancer that has not spread to other parts of the body 
(nonmetastatic). Often, these patients are taking other medicines for common age-related illnesses. Taking more than one 
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medicine at the same time increases the chances of what is known as drug–drug interactions. Drug–drug interactions can 
decrease how well the medicines work or may sometimes increase side effects.
Study Aim To test for possible drug–drug interactions in men with prostate cancer who take darolutamide alongside other 
medicines.
Study Participants Men with nonmetastatic prostate cancer who were being treated with a medicine that lowers testosterone, 
a chemical in the body that causes prostate cancer tumors to grow. Participants took two darolutamide 300 mg tablets, or an 
inactive placebo, twice a day.
What Did the Researchers Measure? The researchers documented the number of medicines taken by each participant and 
the number of other medical conditions that they had. Tests were done to find out whether other medicines affected the way 
that darolutamide works in the body and whether patients taking darolutamide alongside other medicines experienced more 
side effects.
Results As would be expected, based on the typical age of patients with prostate cancer, more than 90% of participants in 
this study used medicines other than darolutamide to manage common age-related illnesses or medical conditions. Taking 
medicines alongside darolutamide did not impact how darolutamide worked in the body and did not increase the number 
of side effects experienced by patients. Darolutamide is known to interact with rosuvastatin, a cholesterol-lowering drug. 
However, in this study, there was no overall increase in side effects among darolutamide-treated patients who took this type 
of drug compared with in those who did not.
Conclusion In this study of patients with nonmetastatic prostate cancer, limited drug–drug interactions were seen when 
taking darolutamide alongside other medicines given to these patients to manage age-related medical conditions.
Key Points 
Polypharmacy for age-related comorbidities is com-
mon in patients with nonmetastatic castration-resistant 
prostate cancer, and this increases the risk of drug–drug 
interactions (DDIs).
Subanalyses of the phase III ARAMIS trial indicate that 
darolutamide has low risk of clinically relevant DDIs 
with comedications commonly used in these patients.
1 Introduction
A prime goal of treatment for patients with nonmetastatic 
castration-resistant prostate cancer (nmCRPC) is to delay 
progression to metastatic disease (mCRPC) since increased 
tumor burden is associated with worse prognosis [1], 
although the recent introduction of multiple life-extending 
therapies for mCRPC (radium-223, abiraterone, enzaluta-
mide, sipuleucel-T, and taxanes) has extended post-progres-
sion survival [2]. Along with disease progression, adverse 
events (AEs) associated with anticancer therapies may have 
a detrimental impact on patients’ quality of life [3], particu-
larly in patients with nmCRPC, given the mostly asymp-
tomatic nature of their disease. As nmCRPC is generally 
diagnosed in older men who are often prescribed multiple 
concomitant medications for comorbid conditions [4–6], the 
risk of AEs or loss of efficacy resulting from drug–drug 
interactions (DDIs) is also a fundamental component in 
clinical decision making [7].
The second-generation androgen receptor inhibitors enza-
lutamide and apalutamide have recently been approved for 
the treatment of nmCRPC after demonstrating significantly 
prolonged metastasis-free survival in phase III clinical tri-
als [8, 9]. However, this change in the treatment landscape 
has also brought decision-making challenges. Apalutamide 
and enzalutamide are associated with higher incidences of 
certain AEs (e.g., falls, fatigue, hypertension, rashes, and 
seizures) than are placebo. They also both have the poten-
tial for DDIs when coadministered with medications that 
are substrates for several metabolizing enzymes and drug 
transporters [8–14]. For example, coadministration of either 
drug may reduce the exposure of medications that are sub-
strates for the cytochrome P450 (CYP) enzymes CYP3A4, 
CYP2C9, and CYP2C19 [15, 16], resulting in loss of activ-
ity of common comedications such as anticoagulants, anti-
hypertensives, opioid analgesics, and proton pump inhibitors 
(PPIs).
Darolutamide is a novel androgen receptor antagonist 
with a unique molecular structure recently approved by the 
US FDA for the treatment of nmCRPC [17, 18]. In the phase 
III ARAMIS trial (NCT02200614), darolutamide demon-
strated significantly prolonged metastasis-free survival com-
pared with placebo (40.4 vs. 18.4 months; hazard ratio for 
metastasis or death in the darolutamide group 0.41; 95% 
confidence interval [CI] 0.34–0.50; p < 0.001) in patients 
with nmCRPC receiving androgen-deprivation therapy and 
delayed time to pain progression (40.3 vs. 25.4 months; haz-
ard ratio 0.65; 95% CI 0.53–0.79) [19]. The DDI potential of 
529Clinically Relevant Drug–Drug Interactions with Darolutamide in the Phase III ARAMIS Trial
darolutamide has been extensively investigated in preclinical 
and clinical phase I studies with metabolizing enzymes and 
drug transporters. Darolutamide was sensitive to induction 
of CYP3A4, the main enzyme mediating its metabolism. 
Inhibition of CYP3A4, P-glycoprotein (P-gp) and breast 
cancer resistance protein (BCRP)—both transporters for 
which darolutamide is a substrate—by comedications was 
not considered clinically relevant. No relevant inhibition of 
any CYP enzymes by darolutamide was observed in vitro, 
and in vivo studies found weak induction of CYP3A4 only, 
suggesting darolutamide may have no clinically relevant 
effect on comedications metabolized by CYP enzymes [20]. 
Therapeutic levels of darolutamide were found to have no 
effect on P-gp substrates [20], though exposure of rosuvasta-
tin, a substrate for BCRP, organic anion-transporting peptide 
(OATP)1B1, and OATP1B3, was moderately increased by 
darolutamide coadministration [21]. This effect was mainly 
attributed to inhibition of BCRP; however, a contribution 
of OATP inhibition is considered likely. Overall, the results 
of these studies indicated that darolutamide has a favorable 
DDI profile.
To evaluate the impact of clinically relevant DDIs with 
darolutamide in the target patient population, we conducted 
prespecified and post hoc analyses in patients with nmCRPC 
who participated in the phase III ARAMIS trial [19], includ-
ing assessments of comorbidities and comedication use, the 
effects of concomitant medications on the pharmacokinetics 
of darolutamide, and the impact of coadministering daroluta-
mide with concomitant medications on patient safety. Given 
that statin use is very common in this population and darolu-
tamide has been observed to increase rosuvastatin exposure 
[21], we conducted a subanalysis of the impact of using con-
comitant statins with darolutamide on patient safety.
2  Patients and Methods
2.1  Trial Design
The phase III ARAMIS trial (NCT02200614) protocol and 
design have been described in detail elsewhere [19]. Briefly, 
this was a randomized, double-blind, placebo-controlled, 
phase III clinical trial conducted globally in 409 centers in 
36 countries to evaluate the efficacy and safety of darolu-
tamide in patients with nmCRPC. The trial was approved 
by local institutional review boards and was conducted in 
compliance with the principles of the Declaration of Hel-
sinki and in accordance with the International Conference 
on Harmonisation guidelines for Good Clinical Practice. All 
patients provided written informed consent.
2.2  Treatment
Men were randomized 2:1 to receive darolutamide 600 mg 
twice daily (given as two 300 mg tablets) or placebo while 
continuing androgen-deprivation therapy. Patients continued 
study medications until protocol-defined progression, dis-
continuation due to AEs, or withdrawal of consent.
2.3  Population Pharmacokinetic Model
An exploratory population pharmacokinetic analysis was 
performed to evaluate the variability in the pharmacokinetics 
of darolutamide, its two pharmacologically active diastere-
omers, (S,R)-darolutamide and (S,S)-darolutamide, and the 
active metabolite, keto-darolutamide, based on data gener-
ated from the phase III ARAMIS study [19]. The population 
pharmacokinetic model was developed using data from a 
subset of patients with valid pharmacokinetic samples col-
lected sparsely at several times during the 12-h application 
interval (detailed in the Electronic Supplementary Material 
[ESM]—Methods) and information on drug disposition 
pathways identified preclinically. The bioanalytical meth-
ods used for pharmacokinetic sampling are summarized in 
the ESM—Methods.
All predefined concomitant medications taken by at least 
one patient during study treatment were included as a covari-
ate in the population pharmacokinetic model (Table 1 in the 
ESM). The impact of BCRP inhibitors, CYP3A4 inducers/
inhibitors, P-gp inducers/inhibitors, PPIs, and/or uridine 
5′-diphospho-glucuronosyltransferase (UGT) inducers/
inhibitors on the pharmacokinetics of darolutamide was 
investigated. Comedications with any relevant DDI poten-
tial, weak or strong, were included.
2.4  Safety Analyses
At each study visit, data on treatment-emergent AEs 
(TEAEs), including type, severity, seriousness, and whether 
they were related to study treatment based on investigator 
assessment, were recorded. A subgroup analysis was also 
performed to compare the incidence of TEAEs for patients 
receiving statins (3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitors) versus those not receiving statins. This 
analysis included all TEAEs reported in concomitant statin 
users versus nonusers regardless of when the event occurred 
during the study, i.e., without consideration for when daro-
lutamide and the statin were coadministered. A post hoc 
analysis evaluating TEAE incidence in patients using statins 
known to be BCRP substrates versus nonusers of BCRP-
substrate statins was also performed.
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2.5  Statistical Analysis
Patient demographics, comorbidities, and concomitant 
medications were summarized descriptively for all rand-
omized patients, i.e., the full analysis set. Comedications 
were categorized according to potential for relevant DDIs 
(CYP inducers/inhibitors/substrates, UGT substrates, and 
drug transporter substrates) based on in vitro and phase I 
clinical studies of darolutamide [21] and established DDI 
profiles for the currently available androgen-receptor inhibi-
tors, enzalutamide and apalutamide [11–14].
Pharmacokinetic model development was conducted via 
nonlinear mixed-effects modelling using NONMEM (ver-
sion 7.3, ICON Development Solutions plc, Manchester, 
UK) and R software [22]. Full details of the population 
pharmacokinetic analysis are given in the ESM—Methods.
Safety evaluations were conducted in all patients who 
were randomized and received at least one dose of study 
medication.
3  Results
3.1  Patients
In total, 1509 men were randomized to darolutamide 
(n = 955) or placebo (n = 554) in addition to androgen-
deprivation therapy. One patient randomized to the daro-
lutamide arm did not receive study treatment and was 
therefore excluded from the safety analyses [19]. Baseline 
demographic and clinical characteristics were similar in the 
two treatment groups (Table 1). Median age was 74 years in 
both groups, and median follow-up time was 17.9 months. 
Most patients had at least one comorbid condition (98.4% 
in both treatment arms); the most common comorbidities 
were hypertension, obesity, anomalies of lipid metabolism, 
and diabetes (Table 2).
3.2  Concomitant Medication Use
The overwhelming majority of men in the trial were receiv-
ing at least one concomitant medication, and rates of come-
dication use were balanced across the two treatment arms: 
98.7% with darolutamide and 98.0% with placebo (Table 3). 
The most common concomitant medications for comorbid 
conditions in darolutamide- versus placebo-treated patients 
were antihypertensives, including drugs affecting the 
renin–angiotensin system (54.7 vs. 49.8%), β-blockers (29.6 
vs. 27.6%), and calcium channel blockers (22.7% in both 
arms), as well as analgesics (53.8 vs. 50.4%), whereas more 
than one-third of patients received antithrombotics (42.8 vs. 
39.7%) or lipid-modifying agents (34.5 vs. 39.4%). Other 
cardiovascular agents, diuretics, urological agents, PPIs, 
systemic antibiotics, and anti-inflammatory/antirheumatic 
agents were used by at least 20% of patients. These come-
dications span a range of agents that act as inducers, inhibi-
tors, or substrates of the enzymes predominantly involved in 
drug metabolism or key drug transporters (e.g., P-gp, BCRP, 
OATP1B1, OATP1B3) (Table 3).
3.3  Population Pharmacokinetic Analysis
In total, 388 patients (40% of the total who received darolu-
tamide in the phase III trial) were included in the pharma-
cokinetic subset. Demographics and baseline characteristics 
were generally similar to those of the overall darolutamide-
treated population, although the pharmacokinetic subset 
contained higher proportions of Japanese patients and 
patients with mild renal impairment (Table 1).
Evaluation of the population pharmacokinetic analysis 
showed that none of the comedications included as covari-
ates in the population pharmacokinetic base model met the 
criteria for a significant covariate effect. These comedica-
tions included CYP3A4 inhibitors (21.6%), P-gp inhibitors 
(20.1%), PPIs (15.2%), BCRP inhibitors (14.9%), UGT1A9 
inhibitors (2.8%), and CYP3A4 inducers (0.5%); examples 
of drugs in these categories are given in Table 3. No patients 
received P-gp or UGT1A9 inducers. PPIs exerted no effect 
on darolutamide clearance. It was not possible to specifi-
cally assess an effect of CYP3A4 inducers as so few patients 
received comedications that were CYP3A4 inducers, such 
as rifampicin or carbamazepine. These data suggest that, 
although preclinical data indicate darolutamide exposure 
may be affected by drugs that are strong CYP3A4 and P-gp 
inducers or inhibitors [23], there was no significant associa-
tion between the use of concomitant medications and the 
pharmacokinetic variability of darolutamide in this study.
3.4  Impact on Adverse Event Incidence of Drugs 
Coadministered with Darolutamide, Including 
Breast Cancer Resistance Protein Substrates
We also assessed whether the DDIs that have been identified 
as clinically relevant for darolutamide (notably, sensitivity to 
strong CYP3A4 inducers and inhibition of BCRP by darolu-
tamide [23]) had a possible impact on the safety of patients 
in the ARAMIS trial population. As already noted, the com-
mon concomitant medications received by patients in ARA-
MIS were similar between study arms (Table 3). We have 
previously reported that the incidence of the most common 
AEs was similar in patients treated with darolutamide and 
those who received placebo, and permanent discontinuations 
of the study drug due to AEs occurred in similar proportions 
of patients in each treatment arm [19].
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Concomitant use of statins was similar in the daroluta-
mide and placebo arms (32.1 vs. 36.5%; Table 4). In both 
treatment arms, the incidence of TEAEs was comparable 
between patients receiving concomitant statins and those 
not receiving statins (88.2 vs. 80.9% for darolutamide and 
82.2 vs. 73.9% for placebo; Table 4). With respect to the 
type of AEs reported (based on system organ class and 
preferred term), no differences among statin users in either 
treatment arm was observed. No meaningful differences in 
alanine aminotransferase (ALT) values occurred between 
concomitant statin users and nonusers: in both treatment 
arms, mean ALT values were slightly higher among sta-
tin users than nonusers at baseline and throughout the 
treatment period. In a subset of patients using statins that 
are BCRP substrates (approximately 30% of the overall 
population; Table 2 in the ESM), predefined AEs known 
to be associated with statins occurred more frequently 
with darolutamide than placebo (8.6 vs. 3.5%; Table 5). 
This difference was due to greater incidences of abnor-
malities in laboratory parameters. A similar difference was 
observed in the overall study population, indicating that 
the difference occurred independently of statin exposure 
and excluding any relevant impact of darolutamide in sta-
tin users. The abnormalities in laboratory parameters were 
notably increased aspartate aminotransferase levels (1.4% 
with darolutamide vs. 0.2% with placebo, respectively) 
and increased blood bilirubin levels (1.3% with daroluta-
mide vs. 0% with placebo).
Table 1  Demographics and baseline characteristics of patients with nonmetastatic castration-resistant prostate cancer in the phase III study
Data presented here are from the 17 January 2019 datacut. Data are presented as median (range) or n (%) unless otherwise indicated
AST aspartate aminotransferase, eGFR estimated glomerular filtration rate, NA not available, PK pharmacokinetic, ULN upper limit of normal
a Full analysis set population (all randomized patients)
b None = eGFR ≥ 90 mL/min, mild = 60 to < 90 mL/min, moderate = 30 to < 60 mL/min, and severe = 15 to < 30 mL/min [28]
c None = total bilirubin and AST ≤ ULN, mild = total bilirubin > ULN to 1.5 × ULN or total bilirubin ≤ ULN and AST > ULN, and moder-
ate = total bilirubin > 1.5 to 3 × ULN with any AST
Characteristics Darolutamide Placeboa (N = 554)
PK subset (n = 388) Overalla (N = 955)
Age (years) 75 (48–95) 74 (48–95) 74 (50–92)
Age group (years)
 < 65 41 (10.6) 113 (11.8) 84 (15.2)
 65–74 140 (36.1) 373 (39.1) 216 (39.0)
 ≥ 75 207 (53.4) 469 (49.1) 254 (45.8)
Race
 Caucasian 292 (75.3) 760 (79.6) 434 (78.3)
 Asian 76 (19.6) 122 (12.8) 71 (12.8)
 Black 12 (3.1) 28 (2.9) 24 (4.3)
 Missing/other 8 (2.1) 45 (4.7) 25 (4.5)
Region
 Asia-Pacific NA 119 (12.5) 67 (12.1)
 Japan 58 (14.9) 62 (6.5) 33 (6.0)
 North America NA 108 (11.3) 76 (13.7)
 Rest of World NA 728 (76.2) 411 (74.2)
 Not Japan 330 (85.1) 893 (93.5) 521 (94.0)
Renal  impairmentb
 None 122 (31.4) 412 (43.1) 230 (41.5)
 Mild 209 (53.9) 423 (44.3) 248 (44.8)
 Moderate 56 (14.4) 119 (12.5) 76 (13.7)
 Severe 1 (0.3) 1 (0.1) 0
Hepatic  impairmentc
 None 356 (91.8) 864 (90.5) 509 (91.9)
 Mild 32 (8.2) 89 (9.3) 43 (7.8)
 Moderate 0 2 (0.2) 1 (0.2)
 Missing 0 0 1 (0.2)
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4  Discussion
The potential for DDIs is an important consideration when 
selecting an androgen receptor-targeting therapy for patients 
with nmCRPC. Loss of efficacy with treatments for patients’ 
comorbidities or sustaining an increased risk of AEs are 
potential outcomes of DDIs [10, 24]. Extensive investigation 
in preclinical/phase I studies indicated that darolutamide has 
a favorable DDI profile. Overall, few DDIs were identified 
at clinically relevant levels: darolutamide was sensitive to 
CYP3A4 induction, but no clinically relevant effects on 
darolutamide were expected from drugs that act as inhibi-
tors of CYP enzymes and drug transporters.
Most importantly, darolutamide had few effects on other 
drugs used to treat comorbid conditions; increased expo-
sure of rosuvastatin was the only interaction of note [23]. 
This interaction was mainly attributed to BCRP inhibition, 
although darolutamide-mediated inhibition of OATP trans-
porters may have contributed to the observed effect. By 
contrast, enzalutamide is a strong CYP3A4 inducer and a 
moderate CYP2C9 and CYP2C19 inducer, and apalutamide 
is a strong inducer of CYP3A4 and CYP2C19 and a weak 
inducer of CYP2C9, UGT, P-gp, BCRP, and OATP1B1 [11, 
14]. Additional monitoring may be required as both drugs 
may lead to suboptimal bioavailability of comedications 
with potential loss of efficacy.
The present analyses of the phase III ARAMIS trial 
demonstrated that almost all patients with nmCRPC receiv-
ing androgen-deprivation therapy with androgen receptor 
inhibitor therapy have comorbid conditions that require the 
use of concomitant medications. Individual patient data in 
ARAMIS indicated that many patients were receiving mul-
tiple comedications, as others have also reported [10]. As 
expected in this population (median age 74 years), the most 
common comorbidities included hypertension and other car-
diovascular disorders, obesity, hyperlipidemia, osteoarthri-
tis, and diabetes. Consistent with the comorbidities reported, 
the most frequently prescribed comedications were antihy-
pertensives and agents for other cardiovascular disorders, 
along with a need for analgesia, treatments for urological 
and acid-related gastrointestinal disorders, antidepressants, 
anxiolytics, and dementia treatments. Our population phar-
macokinetic analysis demonstrated that these frequently 
used concomitant drugs had no significant effect on the 
pharmacokinetics of darolutamide. Comedications that are 
potent CYP3A4 inducers were rarely used by the overall 
ARAMIS population, so the risk of DDIs may also be low 
in clinical practice.
Only the interaction between darolutamide and the com-
bined BCRP and OATP substrate rosuvastatin has been 
deemed clinically relevant [23], though our safety subgroup 
analysis in statin users and nonusers could not clearly attrib-
ute any imbalance between the treatment arms to the effect 
of darolutamide on statins. However, the small sample size 
may preclude observation of rare AEs such as myopathy or 
rhabdomyolysis, although these are well-characterized and 
can readily be monitored. Overall, the incidence of AEs did 
not appear to be increased significantly by DDIs, as similar 
AE rates are reported with darolutamide and placebo despite 
the equally high use of concomitant medications in both 
treatment arms in the ARAMIS study [19]. This observa-
tion includes AEs previously reported more frequently with 
enzalutamide and apalutamide versus placebo in phase III 
trials (PROSPER and SPARTAN, respectively) such as falls, 
hypertension, and central nervous system (CNS)-related AEs 
[8, 9].
The risk of AEs resulting from DDIs is an important con-
sideration for physicians. Enzalutamide and apalutamide 
have been identified as substrates, inducers, and/or inhibi-
tors of metabolizing enzymes and inhibitors or inducers of 
drug transporters [15, 16, 25, 26]. Given that the majority 
of drugs are metabolized by at least one CYP enzyme [4], 
Table 2  Proportion of patients with ongoing comorbid conditions by 
preferred MedDRA term (> 5% of total population; full analysis set)
Data presented here are from the 17 January 2019 datacut
MedDRA Medical Dictionary for Regulatory Activities
Comorbidity (preferred term) Patients with comorbidity, n (%)
Darolu-
tamide 
(N = 955)
Placebo (N = 554)
Hypertension 617 (64.6) 357 (64.4)
Obesity 568 (59.5) 333 (60.1)
Hypercholesterolemia 125 (13.1) 70 (12.6)
Osteoarthritis 122 (12.8) 65 (11.7)
Benign prostatic hyperplasia 103 (10.8) 63 (11.4)
Diabetes mellitus 101 (10.6) 68 (12.3)
Atrioventricular block first degree 86 (9.0) 49 (8.8)
Dyslipidemia 85 (8.9) 51 (9.2)
Type 2 diabetes mellitus 75 (7.9) 53 (9.6)
Hyperlipidemia 74 (7.7) 47 (8.5)
Coronary artery disease 72 (7.5) 39 (7.0)
Arthralgia 71 (7.4) 27 (4.9)
Constipation 70 (7.3) 26 (4.7)
Myocardial ischemia 70 (7.3) 33 (6.0)
Atrial fibrillation 69 (7.2) 43 (7.8)
Bundle branch block, left 64 (6.7) 28 (5.1)
Renal cyst 64 (6.7) 37 (6.7)
Back pain 62 (6.5) 38 (6.9)
Nocturia 60 (6.3) 29 (5.2)
Insomnia 59 (6.2) 36 (6.5)
Hot flush 51 (5.3) 35 (6.3)
Gastroesophageal reflux disease 50 (5.2) 38 (6.9)
Erectile dysfunction 49 (5.1) 36 (6.5)
533Clinically Relevant Drug–Drug Interactions with Darolutamide in the Phase III ARAMIS Trial
Table 3  Concomitant medication use (> 10% of total patient population; full analysis set)
Comedications (by indication and ATC subclass) Patients using comedication, 
n (%)
Examples of drug classes/individual agents with DDI poten-
tial relevant to androgen receptor  inhibitorsc [4, 29, 30]
Daroluta-
mide + ADT 
(N = 955)
Pla-
cebo + ADT 
(N = 554)
Any comedication 943 (98.7) 543 (98.0)
Cardiovascular disease
 Agents acting on the renin–angiotensin system 522 (54.7) 276 (49.8) ACE inhibitors: atenolol (OATP1B1 substrate)
ARBs: losartan (CYP3A4/CYP2C9 substrate), telmisartan 
(OATP1B1 substrate)
 Antithrombotics 409 (42.8) 220 (39.7) Antiplatelet agents: clopidogrel (strong CYP2C8 inhibitor), 
ticagrelor (CYP3A4 substrate)
Anticoagulants: rivaroxaban (CYP3A4 substrate), dabigatran 
etexilate (P-gp substrate)
 Lipid-modifying agents 329 (34.5) 218 (39.4) Statins: atorvastatin (CYP3A4/OATP1B1/BCRP substrate), 
pravastatin (OATP1B1 substrate), rosuvastatin (BCRP/
OATP1B1 substrate)
Gemfibrozil (strong CYP2C8 inhibitor)
 β-blocking agents 283 (29.6) 153 (27.6) Propranolol (CYP2C19 substrate)
 Calcium channel blockers 217 (22.7) 126 (22.7) Amlodipine (CYP3A4 substrate), verapamil (moderate 
CYP3A4 inhibitor, P-gp inhibitor)
 Cardiac therapies (e.g., glycosides, anti-
arrhythmics, anti-anginals)
212 (22.2) 115 (20.8) Glycosides: digoxin (P-gp substrate)
Anti-arrhythmics: amiodarone (CYP3A4 substrate, CYP2C8/
CYP3A4 inhibitor); dronedarone, propafenone (CYP3A4 
substrates)
Anti-anginals: ranolazine (CYP3A4/P-gp substrate, weak 
CYP3A4/P-gp inhibitor)
Spirolactones: eplerenone (CYP3A4 substrate)
 Diuretics 217 (22.7) 102 (18.4) Furosemide (BCRP/OATP1B1 substrate)
 Vasoprotectives 183 (19.2) 113 (20.4) –
Pain and inflammation
 Analgesics 514 (53.8) 279 (50.4) Opioids: fentanyl, oxycodone (CYP3A4/P-gp substrates)
 Anti-inflammatories/DMARDs 249 (26.1) 124 (22.4) Sulfasalazine (BCRP substrate)
Methotrexate (BCRP, OATP1B1, OAT1 and OAT3 substrate)
NSAIDs: celecoxib (CYP2C9 substrate), diclofenac 
(CYP2C9/CYP3A4 substrate)
 Corticosteroids (systemic)a 122 (12.8) 81 (14.6) Dexamethasone (CYP3A4/P-gp inducer)
Urological disorders
 Urologicals 299 (31.3) 176 (31.8) ED agents: sildenafil, vardenafil (CYP3A4 substrates)
BPH treatments: dutasteride, tamsulosin (CYP3A4 sub-
strates); silodosin (CYP3A4/P-gp substrate)
OAB treatments: darifenacin, oxybutynin (CYP3A4 sub-
strates)
GI and metabolic disorders
 Acid-related disorders 281 (29.4) 170 (30.7) PPIs: lansoprazole (CYP2C19 substrate), omeprazole 
(CYP2C19 substrate), rabeprazole (CYP2C19 substrate)
 Antidiabetics 176 (18.4) 119 (21.5) Glitazones: pioglitazone (CYP2C9/CYP3A4 substrate)
Meglitinides: repaglinide (OATP1B1/CY2C8 substrate)
Sulfonylureas: glimepiride (CYP2C9 substrate)
 Antidiarrhealsb 145 (15.2) 95 (17.1) Loperamide: CYP3A4/P-gp substrate
 Constipation medications 156 (16.3) 70 (12.6) –
Infection
 Antibiotics (systemic) 257 (26.9) 138 (24.9) Macrolides: clarithromycin (strong CYP3A4 inhibitor), eryth-
romycin (moderate CYP3A4 inhibitor)
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enzalutamide and apalutamide have the potential for DDIs 
with a range of medications that are commonly used by 
patients with prostate cancer, e.g., gastrointestinal, cardio-
vascular, and analgesic agents (Table 6) [10, 15, 16, 24–26]. 
Consequently, the FDA labels for enzalutamide and apaluta-
mide suggest avoiding the use of susceptible comedications 
and warn of the potential loss of efficacy of these comedi-
cations, respectively [11, 14]. In a retrospective review of 
pharmacy records for patients with mCRPC, enzalutamide 
was associated with a high prevalence of potential DDIs with 
CNS drugs (e.g., opioid analgesics), which could increase 
the risk of cognitive adverse effects, falls, and fractures [10]. 
In addition, enzalutamide reduces plasma concentrations of 
PPIs, which increases the risk of bleeding events in patients 
receiving PPIs in combination with aspirin or nonsteroi-
dal anti-inflammatory drug prophylaxis. Overall, 85% of 
patients with mCRPC who received enzalutamide were at 
risk for DDIs that would require treatment modification of 
at least one comedication [10]. In a post hoc analysis of the 
phase III SPARTAN trial, the risk of falls was increased in 
patients receiving apalutamide and concomitant α-blockers 
or antidepressants [27]. Hence, the safety of prescribing 
androgen receptor inhibitors in the setting of polypharmacy 
warrants consideration by the treating physician.
Limitations of our study include the small sample size 
of the safety subanalyses and the population pharmacoki-
netic analysis and that the population pharmacokinetic 
analysis did not investigate the effect of darolutamide on 
the pharmacokinetics of comedications. Strong CYP3A4 
and P-gp inducers were identified as having a relevant effect 
on darolutamide, but such comedications were rarely used 
in ARAMIS. For example, the strong CYP3A4-inducing 
anti-epileptic drugs, carbamazepine, phenytoin, and pheno-
barbital, were used by few patients. However, as patients 
with severe infections (which may be treated with systemic 
antibiotics such as rifampicin) and other serious comorbidi-
ties (e.g., recent stroke or myocardial infarction, active viral 
hepatitis, or human immunodeficiency virus) were excluded, 
the ARAMIS population did not fully represent the real-
world population likely to receive darolutamide treatment. 
Multiple interactions between drugs were possible since 
many patients received several comedications, but it was 
not possible to assess the impact of these on patient safety 
Table 3  (continued)
Comedications (by indication and ATC subclass) Patients using comedication, 
n (%)
Examples of drug classes/individual agents with DDI poten-
tial relevant to androgen receptor  inhibitorsc [4, 29, 30]
Daroluta-
mide + ADT 
(N = 955)
Pla-
cebo + ADT 
(N = 554)
Nervous system disorders
 Psycholeptics 188 (19.7) 109 (19.7) Antipsychotics: haloperidol, quetiapine, aripiprazole 
(CYP3A4 substrates)
Anxiolytics: buspirone (CYP3A4 substrate)
Carbamazepine (strong CYP3A4 inducer)
Benzodiazepines: alprazolam, midazolam (CYP3A4 sub-
strates); diazepam (CYP2C19 substrate)
 Psychoanaleptics 108 (11.3) 52 (9.4) Bupropion (CYP2B6 substrate)
SARIs: trazodone (CYP3A4 substrate)
SSRIs: citalopram, escitalopram (CYP3A4 substrates)
Dementia treatments: donepezil, galantamine (CYP3A4 
substrates)
Data presented here are from the 17 January 2019 datacut
Includes medications ongoing at baseline or that were initiated after the study drug or after the end of the study drug but excludes any agents 
used locally/topically due to the lack of DDI risk (e.g., ophthalmologicals, nonsystemic respiratory products). As multiple ATC codes per drug 
are possible, some drugs may be counted in more than one category for the same patient
ACE angiotensin-converting enzyme, ADT androgen-deprivation therapy, ARB angiotensin II receptor blocker, ATC Anatomical Therapeutic 
Chemical, BCRP breast cancer resistance protein, BPH benign prostatic hyperplasia, CYP cytochrome P450 enzyme, DDI drug–drug interaction, 
DMARD disease-modifying antirheumatic drug, ED erectile dysfunction, GI gastrointestinal, NSAID nonsteroidal anti-inflammatory drug, OAB 
overactive bladder, OAT organic anion transporter, OATP organic anion-transporting peptide, P-gp P-glycoprotein, PPI proton pump inhibitor, 
SARI serotonin antagonist and reuptake inhibitor, SSRI selective serotonin reuptake inhibitor
a Includes all uses of systemic corticosteroids
b Includes intestinal anti-inflammatory/anti-infective agents
c One or more agent in the drug class
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Table 4  Overview of treatment-emergent adverse events by concomitant statin use (safety population)
This analysis used data from the 17 January 2019 datacut. Data are presented as n (%)
TEAE treatment-emergent adverse event, SAE serious adverse event
a According to investigator’s assessment, with severity graded according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events, version 4.03 [31]
Patients Darolutamide (N = 954) Placebo (N = 554)
Concomitant statin use Concomitant statin use
Yes (n = 306) No (n = 648) Yes (n = 202) No (n = 352)
Any TEAE 270 (88.2) 524 (80.9) 166 (82.2) 260 (73.9)
 Grade 1 73 (23.9) 146 (22.5) 51 (25.2) 83 (23.6)
 Grade 2 95 (31.0) 207 (31.9) 69 (34.2) 97 (27.6)
 Grade 3 76 (24.8) 139 (21.5) 36 (17.8) 63 (17.9)
 Grade 4 10 (3.3) 11 (1.7) 5 (2.5) 4 (1.1)
SAE 97 (31.7) 140 (21.6) 42 (20.8) 69 (19.6)
Death 16 (5.2) 21 (3.2) 5 (2.5) 13 (3.7)
TEAE leading to dose modification 51 (16.7) 84 (13.0) 20 (9.9) 32 (9.1)
TEAE leading to discontinuation of study drug 28 (9.2) 57 (8.8) 16 (7.9) 32 (9.1)
Any drug-related  TEAEa 81 (26.5) 177 (27.3) 43 (21.3) 67 (19.0)
 Grade 1 42 (13.7) 90 (13.9) 31 (15.3) 37 (10.5)
 Grade 2 30 (9.8) 68 (10.5) 7 (3.5) 19 (5.4)
 Grade 3 8 (2.6) 16 (2.5) 4 (2.0) 10 (2.8)
 Grade 4 1 (0.3) 2 (0.3) 0 0
Drug-related SAE 3 (1.0) 7 (1.1) 3 (1.5) 3 (0.9)
Drug-related death 0 1 (0.2) 1 (0.5) 1 (0.3)
Drug-related TEAE leading to dose modification 15 (4.9) 34 (5.2) 5 (2.5) 9 (2.6)
Drug-related TEAE leading to discontinuation of study drug 3 (1.0) 12 (1.9) 5 (2.5) 8 (2.3)
Table 5  Incidence of pre-defined treatment-emergent adverse events with concomitant use of statins that are breast cancer resistance protein sub-
strates (safety population)
This analysis used data from the 19 November 2018 datacut. Data are presented as n (%)
TEAE treatment-emergent adverse event
TEAE (preferred term) Patients with TEAE
Darolutamide (n = 280) Placebo (n = 171)
Any TEAE 24 (8.6) 6 (3.5)
Hepatobiliary disorders 3 (1.1) 0
 Hyperbilirubinemia 3 (1.1) 0
Investigations 20 (7.1) 5 (2.9)
 Blood creatinine increased 10 (3.6) 5 (2.9)
 Aspartate aminotransferase increased 8 (2.9) 0
 Blood bilirubin increased 5 (1.8) 0
 Alanine aminotransferase increased 4 (1.4) 0
 Blood lactate dehydrogenase increased 2 (0.7) 0
 Blood alkaline phosphatase increased 1 (0.4) 0
Musculoskeletal and connective tissue disorders 1 (0.4) 1 (0.6)
 Muscular weakness 1 (0.4) 1 (0.6)
Renal and urinary disorders 1 (0.4) 0
 Renal impairment 1 (0.4) 0
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Table 6  Examples of potential drug–drug interactions between enzalutamide, apalutamide, or darolutamide and concomitant medications
A. Effects of enzalutamide, apalutamide, or darolutamide on the exposure of CYP enzyme or transporter substrates
Enzyme/transporter Apalutamide 
[13, 14]
Enzalutamide 
[11, 12]
Darolutamide 
[23]
Examples of drugs [4, 29, 30, 32, 33]
Effect on substrate exposure
CYP3A4 Analgesics: fentanyl, oxycodone
Anticoagulants: rivaroxaban
Antihypertensives / CV agents: amlodipine, amiodarone,  
dronedarone, felodipine, nisoldipine, ranolazine
Antiplatelet agents: ticagrelor
CNS drugs: alprazolam, buspirone, donepezil, midazolam,  
quetiapine, triazolam
Lipid-modifying agents: lovastatin, simvastatin
Urological agents: avanafil, darifenacin, dutasteride, oxybutynin,  
solifenacin, tamsulosin, tolterodine, vardenafil
CYP2C9 Anticoagulants: warfarin
Antidiabetics: glimepiride
Antihypertensives: losartan
Anti-inflammatories: celecoxib
Lipid-modifying agents: fluvastatin
CYP2C19 Beta-blockers: propanolol
CNS drugs: diazepam
PPIs: lansoprazole, omeprazole, rabeprazole
UGT Analgesics: buprenorphine
Antiretrovirals: zidovudine
CNS drugs: morphine
Anti-epileptics: valproic acid
P-gp Analgesics: fentanyl, oxycodone
Anticoagulants: dabigatran etexilate
CV agents: digoxin, ranolazine
BCRP CV agents: furosemide
Lipid-modifying agents: atorvastatin, rosuvastatin, fluvastatin
DMARDs: sulfasalazine
OATP1B1 Hypertension/CV agents: atenolol
Lipid-modifying agents: atorvastatin, pitavastatin, rosuvastatin,  
pravastatin
Antidiabetics: glyburide, nateglinide, repaglinide
B. Effects of CYP enzyme or drug transporter inhibitors and inducers on the exposure of enzalutamide, apalutamide, or darolutamide
Enzyme/transporter Apalutamide 
[13, 14]
Enzalutamide 
[11, 12]
Darolutamide  
[23]
Examples of drugs [4, 29, 30, 32, 33]
Effect on exposure of apalutamide, enzalutamide  
or darolutamide
Inhibitors
CYP3A4 Antibiotics: clarithromycin, erythromycin
Antifungals: itraconazole, ketoconazole
Antihypertensives: diltiazem, verapamil
Antiretrovirals: indinavir, nelfinavir, ritonavir
CYP2C8 Antibiotics (systemic): trimethoprim
Antiplatelet agents: clopidogrel, gemfibrozil
Inducers
CYP3A4 Anti-epileptics: carbamazepine, phenobarbital
Antibiotics (systemic): rifampicin
P-gp Anti-epileptics: carbamazepine, phenobarbital
Antibiotics (systemic): rifampicin
Systemic corticosteroids: dexamethasone
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in our analyses. Our identification of potential DDIs is not 
exhaustive—DDIs may occur with drugs not investigated 
in preclinical and phase I studies to date, and DDIs may be 
specific to individual drugs within a drug class. The safety 
profile of darolutamide will continue to be monitored in 
post-marketing studies.
5  Conclusions
These analyses of ARAMIS data suggest a limited poten-
tial for clinically relevant DDIs between darolutamide and 
comedications frequently used to treat age-related comorbid-
ities in patients with nmCRPC (Table 6). Interactions noted 
with the combined BCRP and OATP substrate rosuvastatin 
did not seem to translate into increased AEs in the ARAMIS 
trial to date. Determining the risk–benefit balance of andro-
gen receptor-targeted therapies for patients with nmCRPC 
who receive multiple comedications is important for optimal 
management. The findings presented here provide additional 
information for clinical decision making.
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